Arca
Skip to content
Tools
Tools

Warning Letter to Casmara Cosmetics, S.A.

Unspecified. See Casmara Cosmetics's company page or this site's inspections.

On Feb 12, 2018, FDA's CDER sent Casmara Cosmetics, S.A. a warning letter citing process validation, stability, out-of-specification.

  • Letter date: Feb 12, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

• The test methods and specifications you use to analyze each batch of drug product prior to release, including both chemical and microbial quality attributes. Include a summary of all test results obtained from full testing of all batches of OTC drug products intended for the U.S. market still within expiry.

• Timelines for testing all in-date drug products intended for the U.S., for identity and strength of active ingredients and all other appropriate quality attributes, including total count and objectionable microorganisms. If you find that you released any batch for which release test results were found to be out-of-specification, indicate the corrective actions you will take, such as customer notifications and product recalls.

• Batch release specifications for all incoming components. Describe the tests you will conduct for each batch of incoming components.

• A summary of test results obtained from full testing of each of your incoming components to validate suppliers’ certificates of analysis. Include your procedures to ensure that you test for the identity of each incoming lot of components.

• Your procedures to ensure that you test all lots of (b)(4). Provide a current risk assessment of all OTC drug products that contain (b)(4) intended for the U.S. market still within expiry. Provide the results of the testing of retain samples of these lots for (b)(4) and (b)(4).

• A current risk assessment of the OTC drug products intended for the U.S. market still within expiry that are not supported by adequate stability testing.

• Timelines for process performance qualification for each of your drug products. For any drugs distributed to the U.S. before validation activities are completed, provide an interim plan to ensure the quality of drug products that you continue to manufacture and distribute. Provide a detailed summary of your approach for routinely monitoring intra-batch and inter-batch variation.

Recent Letters Citing Process validation

See them all

Record

Recipient
Mr. Jose Sequi Gonzalez
FDA site ID (FEI)
3004619185

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.